Relationship between the expression of Geminin, CDK4 and biological behaviors of colorectal carcinoma

doi:10.3877/cma.j.issn.1674-3946.2018.04.024

Abstract

Abstract:

Objective

To study the relationship between the expression of Geminin and cyclin dependent kinase 4 (CDK4) and the biological behavior and prognosis of colorectal carcinoma.

Methods

50 cases specimen of colorectal carcinoma and complete follow-up data were collected from May 2011 to May 2014. SP immunochemical method was performed to detect the expression of Geminin and CDK4 in 50 cases of colorectal carcinoma, 20 cases of colorectal adenomas and 20 cases of normal colorectal tissues. SPSS 13.0 software was used for statistical analysis. Chi square test and Spearman correlation analysis were used to analyze the data. P<0.05 was statistically significant for the difference.

Results

The positive rates of Geminin and CDK4 in colorectal carcinoma tissues, colorectal adenomas and normal colorectal mucosa tissues group were gradually decreased, and there were significant difference between each group (P<0.05). The expressions of Geminin and CDK4 were closely related to the degree of differentiation, lymph node metastasis, Duke’s stages and the deepness of invasion (P<0.05). The expression of Geminin was positively correlated with CDK4 (P<0.05). The 3 years survival rates after operation in positive expression groups of Geminin (23.8%) and CDK4 (22.5%) were significantly lower than those in negative expression groups (60.0%).

Conclusion

The abnormal expressions of Geminin and CDK4 may participate in the occurrence and development of colorectal carcinorma. The detection of both may be used as an important reference index for clinical judgement of malignancy, metastasis and prognosis of colorectal carcinoma.

Key words: Colorectal Neoplasms, Geminin, Cyclin-Dependent Kinase 4, Immunohistochemistry

Xing Dong, Jing Wang, Bo Yu. Relationship between the expression of Geminin, CDK4 and biological behaviors of colorectal carcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2018, 12(04): 346-348.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2018.04.024

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2018/V12/I04/346

Figures/Tables 3

References 13

[1]	Suchyta M, Miotto B, McGarry TJ. An inactive geminin mutant that binds cdt1[J]. Genes (Basel)，2015,6(2):252-266.
[2]	Zhang L, Cai M, Gong Z, et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis[J]. J Clin Invest，2017,127(6):2159-2175.
[3]	Liu M, Liu H, Chen J. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)[J]. Oncol Rep，2018 ,39(3):901-911.
[4]	Lu F, Lan R, Zhang H, et al. Geminin is partially localized to the centrosome and plays a role in proper centrosome duplication[J]. Biol Cell，2009,101(5):273-285.
[5]	田薇，章建国，刘益飞. Geminin在胃癌组织中的表达及临床意义[J]. 江苏医药，2017,43(15):1093-1095.
[6]	Hernández－Pérez S, Cabrera E, Salido E, et al. DUB3 and USP7 de－ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer[J]. Oncogene，2017,36(33):4817-4817.
[7]	Ikemura S, Aramaki N, Fujii S, et al. Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma[J]. Cancer Sci，2017,108(1):136-142.
[8]	Slawny N, O'Shea KS. Geminin promotes an epithelial－to－mesenchymal transition in an embryonic stem cell model of gastrulation[J]. Stem cells Dev，2013,22(8):1177-1189.
[9]	Ananthula S, Sinha A, El Gassim M, et al. Geminin overexpression－dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers[J]. Oncotarget, 2016,7(15):20869-20889.
[10]	Patel P, Asbach B, Shteyn E，et al.Brk /Protein tyrosine kinase 6 phosphorylates p27KIPI，regulating the activity of CyclinD－Cyclin－ dependent kinase 4[J]. Mol Cell Biol，2015,35(9):1506-1522.
[11]	Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy[J]．Clin Cancer Res，2014,20(13):3379-3383.
[12]	田薇，章建国，刘益飞，等. CDK4和Geminin在胶质瘤中的表达及其与预后的关系[J]. 南京医科大学学报(自然科学版)，2017,37(6):709-713.
[13]	Xu G, Li JY. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component[J]. J Neurooncol，2018 ,136(3):445-452.

病理因素		例数	Geminin			CDK4
病理因素		例数	＋	χ²值	P值	＋	χ²值	P值
性别		?	?	?	?	?	?	?
?	男	32	28	0.810	>0.05	25	0.195	>0.05
?	女	18	14	0.810	>0.05	15	0.195	>0.05
年龄(岁)		?	?	?	?	?	?	?
?	≤40	18	13	2.903	>0.05	16	1.389	>0.05
?	>40	32	29	2.903	>0.05	24	1.389	>0.05
肿瘤大小		?	?	?	?	?	?	?
?	≤3 cm	35	30	0.255	>0.05	30	2.381	>0.05
?	>3 cm	15	12	0.255	>0.05	10	2.381	>0.05
分化程度		?	?	?	?	?	?	?
?	高中分化	27	20	4.303	<0.05	18	6.522	<0.05
?	低分化	23	22	4.303	<0.05	22	6.522	<0.05
浸润深度		?	?	?	?	?	?	?
?	粘膜或浅肌层	20	14	4.861	<0.05	13	4.688	<0.05
?	深肌层或全层	30	28	4.861	<0.05	27	4.688	<0.05
淋巴结转移		?	?	?	?	?	?	?
?	有	31	29	5.534	<0.05	28	5.433	<0.05
?	无	19	13	5.534	<0.05	12	5.433	<0.05
肿瘤分期		?	?	?	?	?	?	?
?	A期	6	2	13.829	<0.01	2	10.016	<0.01
?	B期	21	18			17
?	C期	23	22			21

病理因素		例数	Geminin			CDK4
病理因素		例数	＋	χ²值	P值	＋	χ²值	P值
性别		?	?	?	?	?	?	?
?	男	32	28	0.810	>0.05	25	0.195	>0.05
?	女	18	14	0.810	>0.05	15	0.195	>0.05
年龄(岁)		?	?	?	?	?	?	?
?	≤40	18	13	2.903	>0.05	16	1.389	>0.05
?	>40	32	29	2.903	>0.05	24	1.389	>0.05
肿瘤大小		?	?	?	?	?	?	?
?	≤3 cm	35	30	0.255	>0.05	30	2.381	>0.05
?	>3 cm	15	12	0.255	>0.05	10	2.381	>0.05
分化程度		?	?	?	?	?	?	?
?	高中分化	27	20	4.303	<0.05	18	6.522	<0.05
?	低分化	23	22	4.303	<0.05	22	6.522	<0.05
浸润深度		?	?	?	?	?	?	?
?	粘膜或浅肌层	20	14	4.861	<0.05	13	4.688	<0.05
?	深肌层或全层	30	28	4.861	<0.05	27	4.688	<0.05
淋巴结转移		?	?	?	?	?	?	?
?	有	31	29	5.534	<0.05	28	5.433	<0.05
?	无	19	13	5.534	<0.05	12	5.433	<0.05
肿瘤分期		?	?	?	?	?	?	?
?	A期	6	2	13.829	<0.01	2	10.016	<0.01
?	B期	21	18			17
?	C期	23	22			21

[1]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[2]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[3]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[4]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[5]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[6]	Ting Li, Lin Zhang. Relationship between serum fatty acid metabolites and vitamin D levels and colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 661-665.
[7]	Xu Guan, Xishan Wang. Reflecting on the merits and demerits of regional lymph node management in colorectal cancer based on surgical and immune perspectives [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 448-452.
[8]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[9]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[10]	Xiaoyu Fan, Sizheng Sun, Yimin E, Chunzhao Yu. Different surgical options for obstructive left colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 500-504.
[11]	Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu. Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 396-403.
[12]	Qi Liu, Kai Zhang, Jiannan Li, Tongjun Liu. Current status and progress of biologic treatment for colorectal cancer liver metastases [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 415-419.
[13]	Yin Wu, Zhiqin Chen, Yong Gao, Ming Quan. Progress in diagnosis and treatment of Her-2 positive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 420-425.
[14]	Boyang Fan, Ning Wang, Qian Zhang, Guiyu Wang. The progress in research of molecular mechanism of circRNAs regulating colorectal cancer metastasis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 426-430.
[15]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.

Please choose a citation manager

Content to export